Compare Liquidia Corporation Common Stock (LQDA) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Liquidia Corporation Common Stock vs Marsh & McLennan Companies, Inc. — how do they compare? Liquidia Corporation Common Stock trades at $33.47 (market cap $3.04B), while Marsh & McLennan Companies, Inc. trades at $181.23 (market cap $85.13B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 28× Liquidia Corporation Common Stock's market cap, and Marsh & McLennan Companies, Inc. pays a 2.22% dividend while Liquidia Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Liquidia Corporation Common Stock for 0 Days and Marsh & McLennan Companies, Inc. for 109 Days on average.
| LQDA | MRSH | |
|---|---|---|
Market Cap | $3.04B | $85.13B |
Volume | 21,111,778 | 2,472,018 |
Sector | Health | Financials |
52-Week High | $91.03 | $203.85 |
52-Week Low | $22.02 | $157.32 |
Typical Hold Time | 0 Days | 109 Days |
Enterprise Value | $2.94B | $105.82B |
Dividend Yield | — | 2.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Marsh (MRSH) trades at $177.01, up 0.27% on the day, with a bullish technical signal and strong fundamentals. The company reported revenue of $26.98 billion in 2025, with net income of $4.16 billion and a net margin of 15.41%. Recent earnings have consistently beaten estimates, and the company completed the acquisition of Accel Holdings in October 2026, signaling growth initiatives. Valuation ratios include a P/E of 21.61 and P/S of 3.09, while analyst consensus price target is $202.71.
The outlook for MRSH is positive, supported by earnings beats and strategic acquisitions, but risks include competitive pressures and potential margin compression. Analyst sentiment is mixed with a 'Hold' consensus, suggesting cautious optimism. The stock offers upside to the price target but faces execution risks in integrating acquisitions and maintaining profitability amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Liquidia Corporation Common Stock
Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
